Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS
Jeffrey A. Cohen(Cleveland Clinic), Gordon Francis(Novartis (United States)), Jean Pelletier(Hôpital de la Timone), Frederik Barkhof(Netherlands Institute for Neuroscience), Dieter A. Häring(Novartis (Switzerland)), Bhupendra Khatri(Hope Center for Neurological Disorders), Benjamin Eckert(Novartis (United States)), Xavier Montalbán(Universitat de Vic - Universitat Central de Catalunya), Guillermo Izquierdo(Hospital Universitario Virgen Macarena), Gıancarlo Comı(Vita-Salute San Raffaele University)
Cited by 88
Related Papers
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
|Annals of Neurology|2011|9.8k
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration
|The Lancet Neurology|2013|5.4k
Consistent resting-state networks across healthy subjects
|Proceedings of the National Academy of Sciences|2006|4.4k
Defining the clinical course of multiple sclerosis
|Neurology|2014|3.1k